Cargando…
Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas
TSC-mutated sarcomas are rare molecular and histologic types of sarcoma. Due to the presence of their specific oncogenic driver mutation, these sarcomas are particularly sensitive to mTOR inhibitors. Recently, nab-sirolimus, an albumin-bound mTOR inhibitor, was approved by the Food and Drug Administ...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947835/ https://www.ncbi.nlm.nih.gov/pubmed/36845725 http://dx.doi.org/10.3389/fonc.2023.1046442 |